<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35281325</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2090-6544</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>2022</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Case reports in genetics</Title>
          <ISOAbbreviation>Case Rep Genet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Efficacy of Anti-Tumor Necrosis Factor Therapy in Cryopyrin-Associated Periodic Syndromes: A Report of Two Cases.</ArticleTitle>
        <Pagination>
          <StartPage>2898553</StartPage>
          <MedlinePgn>2898553</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2898553</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2022/2898553</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Cryopyrin-associated periodic syndromes (CAPSs) are a group of autoinflammatory disorders caused by a mutation in the NLRP3 gene. NLRP3 mutations increase inflammasome activation; therefore, IL-1 targeted therapies are frequently used in the aforementioned disorders. <i>Case Presentation</i>. We report two cases of CAPS in which the diagnosis was confirmed by genetic tests and an evaluation of the therapeutic response to anti-tumor necrosis factor (anti-TNF) agents.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">IL-1 inhibitors are highly effective in treating CAPS patients. Most patients with severe symptoms such as neurologic involvement improve with IL-1 blockade. Anti-TNF agents might be effective in reducing mild manifestation; however, they are not effective in improving more severe complications.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Fatemeh Tahghighi et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tahghighi</LastName>
            <ForeName>Fatemeh</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0001-8313-6525</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Children's Medical Center, Pediatrics Center of Excellence, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pediatric Rheumatology Iranian Society, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vahedi</LastName>
            <ForeName>Mahdieh</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-9734-4667</Identifier>
            <AffiliationInfo>
              <Affiliation>Pediatric Rheumatology Iranian Society, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parvaneh</LastName>
            <ForeName>Nima</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0002-3397-9716</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Children's Medical Center, Pediatrics Center of Excellence, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shahrooei</LastName>
            <ForeName>Mohammad</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-4974-3441</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Laboratory of Clinical Bacteriology and Mycology, KU Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ziaee</LastName>
            <ForeName>Vahid</ForeName>
            <Initials>V</Initials>
            <Identifier Source="ORCID">0000-0003-4648-3573</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Children's Medical Center, Pediatrics Center of Excellence, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pediatric Rheumatology Iranian Society, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pediatric Rheumatology Research Group, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Case Rep Genet</MedlineTA>
        <NlmUniqueID>101583302</NlmUniqueID>
        <ISSNLinking>2090-6552</ISSNLinking>
      </MedlineJournalInfo>
      <CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
          <Hour>5</Hour>
          <Minute>20</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35281325</ArticleId>
        <ArticleId IdType="pmc">PMC8913141</ArticleId>
        <ArticleId IdType="doi">10.1155/2022/2898553</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tatjana W., Kuemmerle-Deschner J. B. Diagnosis and management of the cryopyrin-associated periodic syndromes (CAPS): what do we know today? 
Journal of Clinical Medicine
. 2021;10:p. 128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7794776</ArticleId>
            <ArticleId IdType="pubmed">33401496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malcova H., Strizova Z., Milota T, et al.  IL-1 inhibitors in the treatment of monogenic periodic fever syndromes: from the past to the future perspectives. 
Frontiers in Immunology
. 2021;11 doi: 10.3389/fimmu.2020.619257.619257</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.619257</ArticleId>
            <ArticleId IdType="pmc">PMC7884884</ArticleId>
            <ArticleId IdType="pubmed">33603750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A., Tripathy S. K., Phulware R. H., Arava S., Bagri N. K. Cryopyrin‐associated periodic fever syndrome in children: a case‐based review. 
International Journal of Rheumatic Diseases
. 2020;23(2):262–270. doi: 10.1111/1756-185x.13772.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1756-185x.13772</ArticleId>
            <ArticleId IdType="pubmed">31858722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansmann S., Lainka E., Horneff G., et al.  Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative. 
Pediatric Rheumatology Online Journal
. 2020;18:p. 17. doi: 10.1186/s12969-020-0409-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12969-020-0409-3</ArticleId>
            <ArticleId IdType="pmc">PMC7027082</ArticleId>
            <ArticleId IdType="pubmed">32066461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmadinejad Z., Mansouri S., Ziaee V., Aghighi Y., Moradinejad M. H. A review on clinical, management and guideline for Iranian patients—part II. 
Iranian Journal of Pediatrics
. 2014;24:229–240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4276575</ArticleId>
            <ArticleId IdType="pubmed">25562014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torreggiani S., Filocamo G., Esposito S. Recurrent fever in children. 
International Journal of Molecular Sciences
. 2016;17(4):p. 448. doi: 10.3390/ijms17040448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms17040448</ArticleId>
            <ArticleId IdType="pmc">PMC4848904</ArticleId>
            <ArticleId IdType="pubmed">27023528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soriano A., Soriano M., Espinosa G., Manna R., Emmi G., Cantarini L. Current therapeutic options for the main monogenic autoinflammatory diseases and PFAPA syndrome: evidence-based approach and proposal of a practical guide. 
Frontiers in Immunology
. 2020;11:p. 865. doi: 10.3389/fimmu.2020.00865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00865</ArticleId>
            <ArticleId IdType="pmc">PMC7325944</ArticleId>
            <ArticleId IdType="pubmed">32655539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Landmann E. C., Walker U. A. Pharmacological treatment options for cryopyrin-associated periodic syndromes. 
Expert Review of Clinical Pharmacology
. 2017;10(8):855–864. doi: 10.1080/17512433.2017.1338946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17512433.2017.1338946</ArticleId>
            <ArticleId IdType="pubmed">28586272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakanishi H., Kawashima Y., Kurima K., et al.  NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy. 
Proceedings of the National Academy of Sciences
. 2017;114(37):E7766–E7775. doi: 10.1073/pnas.1702946114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1702946114</ArticleId>
            <ArticleId IdType="pmc">PMC5604003</ArticleId>
            <ArticleId IdType="pubmed">28847925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuemmerle-Deschner J. B., Wittkowski H., Tyrrell P. N., et al.  Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. 
Arthritis Research &amp; Therapy
. 2013;15(3):p. R64. doi: 10.1186/ar4237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar4237</ArticleId>
            <ArticleId IdType="pmc">PMC4060562</ArticleId>
            <ArticleId IdType="pubmed">23718630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vahedi M., Parvaneh N., Vahedi S., Shahrooei M., Ziaee V. Identification of a new variant in NLRP3 gene by Whole exome sequencing in a patient with cryopyrin-associated periodic syndrome. 
Case Reports in Immunolology
. 2021;2021:4. doi: 10.1155/2021/2023119.2023119</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2021/2023119</ArticleId>
            <ArticleId IdType="pmc">PMC8384535</ArticleId>
            <ArticleId IdType="pubmed">34447596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naz Villalba E., Gomez de la Fuente E., Caro Gutierrez D., et al.  Muckle-Wells syndrome: a case report with anNLRP3T348M mutation. 
Pediatric Dermatology
. 2016;33(5):e311–e314. doi: 10.1111/pde.12905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/pde.12905</ArticleId>
            <ArticleId IdType="pubmed">27435956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fingerhutová Š., Fráňová J., Hlaváčková E., et al.  Muckle-Wells syndrome across four generations in one Czech family: natural course of the disease. 
Frontiers in Immunology
. 2019;10:p. 802. doi: 10.3389/fimmu.2019.00802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.00802</ArticleId>
            <ArticleId IdType="pmc">PMC6477140</ArticleId>
            <ArticleId IdType="pubmed">31057541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kümmerle-Deschner J. B., Tyrrell P. N., Reess F., et al.  Risk factors for severe Muckle-Wells syndrome. 
Arthritis &amp; Rheumatism
. 2010;62:3783–3791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20722029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuemmerle-Deschner J. B., Koitschev A., Ummenhofer K., et al.  Hearing loss in Muckle-Wells syndrome. 
Arthritis &amp; Rheumatism
. 2013;65(3):824–831. doi: 10.1002/art.37810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.37810</ArticleId>
            <ArticleId IdType="pubmed">23440695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maksimovic L., Stirnemann J., Caux F., et al.  New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. 
Rheumatology (Oxford, England)
. 2008;47:309–310. doi: 10.1093/rheumatology/kem318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kem318</ArticleId>
            <ArticleId IdType="pubmed">18174231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kortus-Götze B., Joachim H. Successful renal transplantation in Muckle-Wells syndrome treated with anti-IL-1β-monoclonal antibody. 
Nephrology Dialysis Transplantation
. 2011;4:404–405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4421672</ArticleId>
            <ArticleId IdType="pubmed">25984207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aoyama K., Amano H., Takaoka Y., Nishikomori R., Ishikawa O. Cryopyrin-associated periodic syndrome: a case report and review of the Japanese literature. 
Acta Dermato Venereologica
. 2012;92(4):395–398. doi: 10.2340/00015555-1322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2340/00015555-1322</ArticleId>
            <ArticleId IdType="pubmed">22377911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kilic H., Sahin S., Duman C., et al.  Spectrum of the neurologic manifestations in childhood-onset cryopyrin-associated periodic syndrome. 
European Journal of Paediatric Neurology
. 2019;23(3):466–472. doi: 10.1016/j.ejpn.2019.03.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpn.2019.03.006</ArticleId>
            <ArticleId IdType="pubmed">30967326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banoth B., Sutterwala F. S. Confounding role of tumor necrosis factor in cryopyrin-associated periodic syndromes. 
Journal of Clinical Investigation
. 2017;127(12):4235–4237. doi: 10.1172/jci98322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci98322</ArticleId>
            <ArticleId IdType="pmc">PMC5707140</ArticleId>
            <ArticleId IdType="pubmed">29130931</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
